Serena Wang’s Post

The FDA has granted accelerated approval to a new treatment option for patients with BRAF V600E-positive metastatic colorectal cancer (mCRC). This approval signifies a significant step forward in targeted therapy for mCRC. The regimen combines encorafenib (Braftovi), cetuximab (Erbitux), and mFOLFOX6.

Pembrolizumab with chemotherapy improves both PFS and OS in cervical cancer patients... https://lnkd.in/gStvxqUA #cervicalcancer #immunotherapy #pembrolizumab

Key question for the use of enfortumab vedotin (Padcev) in patients with advanced urothelial (bladder) cancer: If I have to reduce the dose for side effects in someone who is responding to the drug, will it compromise the tumor response? Probably not. That's what was observed in the phase 3 trial that led to the initial approval of the drug based on analysis reported at #ASCO24 (Abstract 4503). Important information for those who use this drug in practice. https://lnkd.in/eD9X2_Wr

Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial https://lnkd.in/grmFDZdG

Thromboembolic and Cardiovascular Adverse Events with PARP Inhibitor Treatment in Patients with mCRPC - Andrea Necchi https://lnkd.in/de7zVqmz Brigida Anna Maiorano Martina Catalano Chiara Mercinelli Antonio Cigliola Valentina Tateo Neeraj Agarwal, MD, FASCO Shilpa Gupta, MD #Cancer #CancerResearch #CancerTreatment #ProstateCancer #PARPInhibitor #CancerDrug #Medicine #Health #Oncology #OncoDaily

Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A Review. https://lnkd.in/efv44gYe

Helpful summary about guidelines update in IV stage oncogene addicted NSCLC according to American Society of Clinical Oncology (ASCO) Something you wish you had in your agenda

Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study.

Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2–Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial https://buff.ly/3Pu0ttA The phase III EMERALD trial investigated the noninferiority of eribulin compared to taxane, both combined with trastuzumab-pertuzumab (HP), as first-line treatment for locally advanced/metastatic HER2+ #BreastCancer . The study enrolled 446 patients, randomly assigned to receive either eribulin or a taxane (docetaxel or paclitaxel) plus HP. The primary endpoint was progression-free survival (PFS). The median PFS was 14.0 months for eribulin and 12.9 months for the taxane group, confirming noninferiority (HR, 0.95). Median overall survival (OS) was 65.3 months for the taxane group but not yet reached for the eribulin group. Quality of life (QoL) deterioration was delayed with eribulin, and adverse events were comparable, though specific side effects varied. These results suggest eribulin + HP is a viable first-line option for HER2+ breast cancer. Shigehira Saji Toshimi Takano Yoichi Naito Junji Tsurutani Satoshi Morita

U.S. FDA approved the first targeted medicine for the treatment of patients with relapsed or refractory pediatric low-grade glioma - Day One Biopharmaceuticals https://lnkd.in/ghbUkbzv #oncodaily #oncology #cancer #FDAapproval #pediatriccancer #glioma #BRAFmutation #targetedtherapy #medicalbreakthrough #clinicaltrial #healthcare #cancerresearch